Numerous studies have established that gastroenteropancreatic endocrine tumours
(carcinoids and pancreatic endocrine tumours) resemble a number of other tumours in …

Objectives: This study evaluates the diagnostic and therapeutic implications of somatostatin-
receptor scintigraphy in the management of patients with proven or high clinical suspicion of …

BACKGROUND: Somatostatin receptor imaging with 111In-pentetreotide is widely accepted
as an essential step in the management of patients affected by neuroendocrine tumours of …

Somatostatin receptor imaging (SRI) with [111In-DTPA0] octreotide has proven its role in the
diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). Newer …

Somatostatin receptor scintigraphy (SRS) is positive in approximately 75% of all patients
with neuroendocrine gastroenteropancreatic tumours. This study aimed to identify specific …

Somatostatin receptors (SS-Rs) have been found on a variety of neuroendocrine tumors like
carcinoids, paragangliomas, as well as on brain and breast tumors. SS-Rs are also present …

Neuroendocrine tumours displaying somatostatin receptors have been successfully
visualised with somatostatin receptor imaging (SRI). However, there may be differences in …

Background: Gastroenteropancreatic neuroendocrine tumors are often difficult to localize.
This study was conducted to examine the value of somatostatin-receptor scintigraphy for …

Treatment with radiolabeled somatostatin analogs is a promising new tool in the
management of patients who have inoperable or metastasized endocrine tumors …

Peptide receptor radionuclide therapy is a new treatment modality for patients with
inoperable or metastasised neuroendocrine gastroenteropancreatic tumours. After the …